Market Cap 740.18M
Revenue (ttm) 0.00
Net Income (ttm) -695.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 661,700
Avg Vol 1,024,712
Day's Range N/A - N/A
Shares Out 54.19M
Stochastic %K 48%
Beta 1.71
Analysts Strong Sell
Price Target $36.14

Company Profile

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 655 6580
Address:
500 Boylston Street, Suite 1350, Boston, United States
SuperGreenToday
SuperGreenToday Jun. 2 at 2:12 AM
0 · Reply
AIBioScanner
AIBioScanner May. 19 at 3:18 PM
$VOR AI-Based Findings on VOR After running VOR through my AI-driven quantitative framework, the stock is in a downtrend with price falling below both moving averages amid weakening momentum. VOR is trading around $14.13, below both the 20-day (~$15.06) and 50-day (~$14.98) moving averages — indicating continued selling pressure and softening structure. Key signals: • Trading below both MAs — downtrend • MACD negative (-0.05) — bearish momentum • Range between ~$13.81 support and ~$18.05 resistance 1-Month Outlook: Base scenario: consolidation near $12.01–$16.25 Breakout above $16.25 could open a move toward $19.01 Breakdown below $12.01 may extend further downside toward $9.85 Structure is bearish. Requires significant catalyst or volume reversal for recovery. Not financial advice.
0 · Reply
shauntg
shauntg May. 18 at 9:30 PM
Watching $VOR for a potential squeeze at some point. Free Float 28M. Short approximately 5M shares. Days to cover 4+. While not a strong case for a squeeze, it's worth keeping on a watchlist. Prior pricing was above $50 giving this stock room to run. Potential Catalyst: VOR advanced its Phase 3 telitacicept trial in myasthenia gravis in May 2026, keeping institutional attention elevated. A positive data readout or partnership/licensing deal would be the most credible igniter. Multiple Wall Street desks including JPMorgan (Overweight, $40 PT) and HC Wainwright (Buy) remain bullish, which means there's a sentiment gap between analysts and the short sellers — that tension is exactly what you want on the long side if a catalyst hits.
0 · Reply
theBigDollarski
theBigDollarski Apr. 30 at 10:25 PM
$VOR looks ripe
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 27 at 5:43 PM
$VOR Current Stock Price: $13.96
0 · Reply
YakoCapital
YakoCapital Apr. 27 at 3:51 PM
0 · Reply
Multiplyme7x
Multiplyme7x Apr. 25 at 12:28 PM
$XLO this is the same set up at $STRO stayed below $1 for many months then had a reverse split a few months after the split started going up now its above $30 check them out , $VOR and $LYEL also had reverse splits and headed north after a few months of nothing .
0 · Reply
Arcides
Arcides Apr. 20 at 3:11 PM
$VOR piece of shit...not what you wanna see after a pocket pivot
1 · Reply
RunnerSignals
RunnerSignals Apr. 15 at 7:45 PM
early signals vs priced moves $TVTX +33% $ZM +7% $VOR -2.8% rsi + volume flagged early. price followed. most traders react late. that gap is where edge exists
1 · Reply
DARKP00L
DARKP00L Apr. 15 at 11:09 AM
$VOR 06:51 on Apr. 15 2026 HC Wainwright & Co. Maintains Buy on Vor Biopharma, Lowers Price Target to $31 #tradeideas
0 · Reply
Latest News on VOR
Vor Bio price target raised to $18 from $15 at Wedbush

2026-05-14T17:08:10.000Z - 21 days ago

Vor Bio price target raised to $18 from $15 at Wedbush


Vor Biopharma Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 22 days ago

Vor Biopharma Quarterly report: Q1 2026


Vor Biopharma Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 22 days ago

Vor Biopharma Earnings release: Q1 2026


Vor Biopharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Vor Biopharma Proxy statement: Proxy filing


Vor Biopharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Vor Biopharma Proxy statement: Proxy filing


Vor Biopharma Registration statement: Registration filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Vor Biopharma Registration statement: Registration filing


Vor Bio price target raised to $15 from $9 at Wedbush

2026-03-31T11:58:58.000Z - 2 months ago

Vor Bio price target raised to $15 from $9 at Wedbush


Vor Bio price target lowered to $40 from $55 at Stifel

2026-03-30T18:36:48.000Z - 2 months ago

Vor Bio price target lowered to $40 from $55 at Stifel


Vor Bio price target lowered to $40 from $55 at Stifel

2026-03-30T18:30:12.000Z - 2 months ago

Vor Bio price target lowered to $40 from $55 at Stifel


Vor Bio doses first patient in UPSTREAM SjD study

2026-03-30T12:25:44.000Z - 2 months ago

Vor Bio doses first patient in UPSTREAM SjD study


Vor Biopharma Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 2 months ago

Vor Biopharma Earnings release: Q4 2025


Vor Biopharma Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 2 months ago

Vor Biopharma Annual report: Q4 2025


Vor Bio initiated with a Buy at Jefferies

2026-03-29T23:30:08.000Z - 2 months ago

Vor Bio initiated with a Buy at Jefferies


Vor Bio to sell 5.338M shares at $14.05 in private placement

2026-03-27T12:27:35.000Z - 2 months ago

Vor Bio to sell 5.338M shares at $14.05 in private placement


Vor Bio Announces $75 Million Private Placement with TCGX

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Vor Bio Announces $75 Million Private Placement with TCGX


Vor Bio initiated with an Overweight at Wells Fargo

2026-03-19T10:01:01.000Z - 2 months ago

Vor Bio initiated with an Overweight at Wells Fargo


Vor Biopharma Slides: Corporate presentation

Mar 6, 2026, 6:00 AM EST - 3 months ago

Vor Biopharma Slides: Corporate presentation


Vor Biopharma Registration statement: Registration Filing

Jan 29, 2026, 7:00 AM EST - 4 months ago

Vor Biopharma Registration statement: Registration Filing


Vor Bio initiated with a Buy at Citi

2026-01-09T11:15:37.000Z - 5 months ago

Vor Bio initiated with a Buy at Citi


Vor Bio price target lowered to $46 from $64 at Baird

2025-12-23T12:00:24.000Z - 5 months ago

Vor Bio price target lowered to $46 from $64 at Baird


Vor Bio price target lowered to $40 from $43 at JPMorgan

2025-12-19T12:00:56.000Z - 5 months ago

Vor Bio price target lowered to $40 from $43 at JPMorgan


Vor Bio initiated with a Buy at TD Cowen

2025-12-17T10:40:21.000Z - 6 months ago

Vor Bio initiated with a Buy at TD Cowen


Vor Bio prices 13.88M shares at $10.81 in private placement

2025-12-15T13:05:06.000Z - 6 months ago

Vor Bio prices 13.88M shares at $10.81 in private placement


Vor Bio Announces $150 Million Private Placement

Dec 15, 2025, 8:00 AM EST - 6 months ago

Vor Bio Announces $150 Million Private Placement


Vor Bio initiated with an Overweight at JPMorgan

2025-12-09T10:00:19.000Z - 6 months ago

Vor Bio initiated with an Overweight at JPMorgan


Vor Bio assumed with a Neutral at Wedbush

2025-11-25T13:41:07.000Z - 6 months ago

Vor Bio assumed with a Neutral at Wedbush


Vor Bio price target lowered to $32 from $55 at H.C. Wainwright

2025-11-14T11:15:57.000Z - 7 months ago

Vor Bio price target lowered to $32 from $55 at H.C. Wainwright


Vor Biopharma Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 7 months ago

Vor Biopharma Earnings release: Q3 2025


Vor Biopharma Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 7 months ago

Vor Biopharma Quarterly report: Q3 2025


Vor Biopharma Registration statement: Registration Filing

Nov 10, 2025, 7:00 AM EST - 7 months ago

Vor Biopharma Registration statement: Registration Filing


Vor Bio to Participate in Upcoming Investor Conferences

Nov 7, 2025, 8:00 AM EST - 7 months ago

Vor Bio to Participate in Upcoming Investor Conferences


Vor Biopharma Slides: Corporate Presentation

Nov 3, 2025, 6:00 PM EST - 7 months ago

Vor Biopharma Slides: Corporate Presentation


Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Nov 3, 2025, 8:00 AM EST - 7 months ago

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer


Vor Biopharma Transcript: Study Update

Oct 28, 2025, 4:30 PM EDT - 7 months ago

Vor Biopharma Transcript: Study Update


Vor Biopharma Press release: Study Update

Oct 28, 2025, 4:30 PM EDT - 7 months ago

Vor Biopharma Press release: Study Update


Vor Biopharma Slides: Study Update

Oct 28, 2025, 4:30 PM EDT - 7 months ago

Vor Biopharma Slides: Study Update


Vor Biopharma Registration statement: Registration Filing

Sep 24, 2025, 8:00 AM EDT - 9 months ago

Vor Biopharma Registration statement: Registration Filing


Vor Bio Appoints Navid Z. Khan, Ph.D.

Sep 23, 2025, 8:00 AM EDT - 9 months ago

Vor Bio Appoints Navid Z. Khan, Ph.D.


Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel


Vor Biopharma Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 10 months ago

Vor Biopharma Quarterly report: Q2 2025


Vor Biopharma Proxy statement: Proxy Filing

Aug 8, 2025, 8:00 AM EDT - 10 months ago

Vor Biopharma Proxy statement: Proxy Filing


Vor Biopharma Proxy statement: Proxy Filing

Jul 29, 2025, 8:00 AM EDT - 11 months ago

Vor Biopharma Proxy statement: Proxy Filing


Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Jul 17, 2025, 8:30 AM EDT - 11 months ago

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer


Vor Bio Announces $175 Million Private Placement

Jun 25, 2025, 4:50 PM EDT - 1 year ago

Vor Bio Announces $175 Million Private Placement


Vor Biopharma Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Vor Biopharma Quarterly report: Q1 2025


Vor Biopharma Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing


Vor Biopharma Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing


Vor Biopharma Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing


Vor Biopharma Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing


Vor Biopharma Registration statement: Registration Filing

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Registration statement: Registration Filing


Vor Biopharma Earnings release: Q4 2024

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Vor Biopharma Earnings release: Q4 2024


Vor Biopharma Annual report: Q4 2024

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Vor Biopharma Annual report: Q4 2024


Vor Biopharma Registration statement: Registration Filing

Jan 21, 2025, 7:00 AM EST - 1 year ago

Vor Biopharma Registration statement: Registration Filing


Vor Bio Announces $55.6 Million Private Placement

Dec 27, 2024, 9:00 AM EST - 1 year ago

Vor Bio Announces $55.6 Million Private Placement


Vor Biopharma Transcript: Status Update

Dec 9, 2024, 8:00 AM EST - 1 year ago

Vor Biopharma Transcript: Status Update


Vor Biopharma Press release: Status Update

Dec 9, 2024, 8:00 AM EST - 1 year ago

Vor Biopharma Press release: Status Update


Vor Biopharma Slides: Status Update

Dec 9, 2024, 8:00 AM EST - 1 year ago

Vor Biopharma Slides: Status Update


Vor Biopharma Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 2:25 PM EST - 1 year ago

Vor Biopharma Transcript: Stifel 2024 Healthcare Conference


Vor Biopharma Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Vor Biopharma Earnings release: Q3 2024


Vor Biopharma Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Vor Biopharma Quarterly report: Q3 2024


Vor Biopharma Transcript: Study Update

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Vor Biopharma Transcript: Study Update


Vor Biopharma Press release: Study Update

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Vor Biopharma Press release: Study Update


Vor Biopharma Slides: Study Update

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Vor Biopharma Slides: Study Update


Vor Biopharma Quarterly report: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 1 year ago

Vor Biopharma Quarterly report: Q2 2024


Vor Biopharma Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Vor Biopharma Quarterly report: Q1 2024


Vor Biopharma Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Vor Biopharma Earnings release: Q1 2024


SuperGreenToday
SuperGreenToday Jun. 2 at 2:12 AM
0 · Reply
AIBioScanner
AIBioScanner May. 19 at 3:18 PM
$VOR AI-Based Findings on VOR After running VOR through my AI-driven quantitative framework, the stock is in a downtrend with price falling below both moving averages amid weakening momentum. VOR is trading around $14.13, below both the 20-day (~$15.06) and 50-day (~$14.98) moving averages — indicating continued selling pressure and softening structure. Key signals: • Trading below both MAs — downtrend • MACD negative (-0.05) — bearish momentum • Range between ~$13.81 support and ~$18.05 resistance 1-Month Outlook: Base scenario: consolidation near $12.01–$16.25 Breakout above $16.25 could open a move toward $19.01 Breakdown below $12.01 may extend further downside toward $9.85 Structure is bearish. Requires significant catalyst or volume reversal for recovery. Not financial advice.
0 · Reply
shauntg
shauntg May. 18 at 9:30 PM
Watching $VOR for a potential squeeze at some point. Free Float 28M. Short approximately 5M shares. Days to cover 4+. While not a strong case for a squeeze, it's worth keeping on a watchlist. Prior pricing was above $50 giving this stock room to run. Potential Catalyst: VOR advanced its Phase 3 telitacicept trial in myasthenia gravis in May 2026, keeping institutional attention elevated. A positive data readout or partnership/licensing deal would be the most credible igniter. Multiple Wall Street desks including JPMorgan (Overweight, $40 PT) and HC Wainwright (Buy) remain bullish, which means there's a sentiment gap between analysts and the short sellers — that tension is exactly what you want on the long side if a catalyst hits.
0 · Reply
theBigDollarski
theBigDollarski Apr. 30 at 10:25 PM
$VOR looks ripe
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 27 at 5:43 PM
$VOR Current Stock Price: $13.96
0 · Reply
YakoCapital
YakoCapital Apr. 27 at 3:51 PM
0 · Reply
Multiplyme7x
Multiplyme7x Apr. 25 at 12:28 PM
$XLO this is the same set up at $STRO stayed below $1 for many months then had a reverse split a few months after the split started going up now its above $30 check them out , $VOR and $LYEL also had reverse splits and headed north after a few months of nothing .
0 · Reply
Arcides
Arcides Apr. 20 at 3:11 PM
$VOR piece of shit...not what you wanna see after a pocket pivot
1 · Reply
RunnerSignals
RunnerSignals Apr. 15 at 7:45 PM
early signals vs priced moves $TVTX +33% $ZM +7% $VOR -2.8% rsi + volume flagged early. price followed. most traders react late. that gap is where edge exists
1 · Reply
DARKP00L
DARKP00L Apr. 15 at 11:09 AM
$VOR 06:51 on Apr. 15 2026 HC Wainwright & Co. Maintains Buy on Vor Biopharma, Lowers Price Target to $31 #tradeideas
0 · Reply
G101SPM
G101SPM Apr. 13 at 2:08 PM
#INSIDERS $DBD 10% owner Millstreet Capital sold 399,929 shares worth approximately $33 mln (transaction date 4/8). $VOR 10% owner RA Capital sold 620,133 shares worth approximately $10.2 mln (transaction date 4/8-4/10).
0 · Reply
look2hook
look2hook Apr. 7 at 5:13 PM
$VOR Got back in at 15. Let's push this thing!
0 · Reply
ODLH
ODLH Apr. 6 at 10:53 PM
$VOR Insider RA CAPITAL MANAGEMENT, LLC reports selling 849,257 shares of VOR / Vor Biopharma Inc. at a total cost of $14,518,963.47 P&D?
1 · Reply
GSP
GSP Apr. 5 at 9:32 PM
0 · Reply
look2hook
look2hook Apr. 1 at 1:30 PM
$VOR Let's close above the 200 day MA today!
0 · Reply
STACKD0E
STACKD0E Apr. 1 at 1:22 PM
$VOR 🙃✨️
0 · Reply
Bobbydicrec
Bobbydicrec Apr. 1 at 10:42 AM
$VOR where do we see this thing going? $100,200, more? What’s the Q2 expectation for it people
3 · Reply
FonsieTrader
FonsieTrader Apr. 1 at 9:17 AM
$VOR 🚨 Heating up in pre-market. And the chart says the wedge just BROKE. 💥 📊 Daily chart: • TTM Squeeze FIRED OFF 🟢 • RSI at 68 = strong momentum building • MFI at 44 = NEUTRAL = massive room to run • OBV steady uptrend = accumulation intact • Ascending wedge breakout ✅ • BB expanding UP out of Keltner • MA200 at $23.71 = the magnet 🧲 Pivot map: 🎯 $19 resistance 🎯 $23.71 MA200 target 🎯 $23.71+ full measured move (+30.8%) The DD — this is SERIOUS: • Mar 27: $75M private placement CLOSED 🚨 • Led by NEW investor TCGX • Cash position: $530M — funded into 2029 • NO placement agent = zero dilution fees • Phase 3 trials running for: → Generalized Myasthenia Gravis (gMG) → Sjögren’s Disease (SjD) • Topline data gMG = H1 2027 catalyst • Hiring surge — 215,700 new stock options granted A new institutional investor just put $75 MILLION in at $14.05/share. Stock is NOW at $17.84. That’s already +27% above their entry. Smart money is smiling. $VOR #biotech #autoimmune #squeeze
1 · Reply
GSP
GSP Mar. 31 at 11:45 PM
0 · Reply
GSP
GSP Mar. 31 at 9:56 PM
No video tonight, but here's what I'm watching tomorrow. $ASTC $GVH $NAVN $VOR $JAGU
0 · Reply
IBWiLL
IBWiLL Mar. 31 at 8:12 PM
$VOR 👀
0 · Reply
STACKD0E
STACKD0E Mar. 31 at 2:21 PM
$VOR 🙃✨️
0 · Reply